Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma
Latest Information Update: 11 Jul 2019
At a glance
- Drugs Tivantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 15 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.